Valuation: Genelux Corporation

Market Cap 91.86M 82.45M 76.13M 69.04M 129M 8.73B 131M 913M 362M 4.57B 345M 337M 14.5B P/E 2026 *
-2.51x
P/E 2027 * -2.61x
Enterprise Value 91.86M 82.45M 76.13M 69.04M 129M 8.73B 131M 913M 362M 4.57B 345M 337M 14.5B EV / Sales 2026 *
-
EV / Sales 2027 * 11.7x
Free-Float
86.3%
Yield 2026 *
-
Yield 2027 * -
1 day+7.33%
1 week-18.00%
Current month-18.97%
1 month-17.34%
3 months-30.51%
6 months-19.92%
Current year-52.98%
1 week 1.86
Extreme 1.86
2.35
1 month 1.86
Extreme 1.86
2.66
Current year 1.86
Extreme 1.86
4.99
1 year 1.86
Extreme 1.86
8.54
3 years 1.6
Extreme 1.6
18.01
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 2014-05-27
Director of Finance/CFO 42 2025-01-29
Chief Tech/Sci/R&D Officer 52 2026-01-01
Director TitleAgeSince
Director/Board Member 68 2002-08-31
Chairman 73 2013-12-31
Chairman 67 2023-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Sell

Chief Technology Officer

-9,683 0.0214%
8/31/26 Sell

Chief Executive Officer

-34,463 0.0762%
8/31/26 Sell

Chief Technology Officer

-10,257 0.0227%
Change 5-day change 1-year change 3-year change Capi.($)
+7.33%-18.00%-71.92%-84.52% 85.59M
-3.10%-4.19%+32.67%+59.47% 65.28B
+0.33%+0.33%+10.16%+78.07% 54.57B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 45.03B
-1.30%-4.80%+16.05%+114.76% 42.17B
+1.26%-5.26%+221.12%+900.64% 39.42B
-0.74%-4.46%+11.00%+44.65% 32.71B
+1.11%+15.18%+60.27%+49.33% 26.5B
+3.18%-6.72%+25.35%-8.75% 24.01B
Average +0.75%-1.95%+33.95%+130.67% 38.34B
Weighted average by Cap. -0.35%-0.59%+42.49%+153.37%

Financials

2026 *2027 *
Net sales - 7.85M 7.04M 6.5M 5.9M 11.02M 746M 11.16M 77.98M 30.97M 391M 29.46M 28.83M 1.24B
Net income -36.96M -33.17M -30.63M -27.78M -51.91M -3.51B -52.55M -367M -146M -1.84B -139M -136M -5.84B -40.91M -36.72M -33.9M -30.74M -57.46M -3.89B -58.16M -406M -161M -2.04B -154M -150M -6.46B
Net Debt - -
Projected Income Statement - Annual - Genelux Corporation
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
26-10-27 US$2.050 +7.33% 1,452,184
26-10-26 US$1.910 -4.50% 494,701
26-10-23 US$2.000 +1.01% 648,745
26-10-22 US$1.980 -4.35% 947,444
26-10-21 US$2.070 -17.20% 850,725
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Genelux Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.050USD
Average target price
18.83USD
Spread / Average Target
+818.70%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Genelux Corporation
  1. Stock Market
  2. Stocks
  3. GNLX Stock